

# 1 Comparison of single-cell whole-genome amplification strategies

2 Nuria Estévez-Gómez<sup>1,2,3#</sup>, Tamara Prieto<sup>1,2,3#</sup>, Amy Guillaumet-Adkins<sup>4,5§</sup>, Holger Heyn<sup>4,5</sup>, Sonia  
3 Prado-López<sup>1,2,3\*</sup> & David Posada<sup>1,2,3\*</sup>

4 <sup>1</sup>Department of Biochemistry, Genetics and Immunology, University of Vigo, 36310 Vigo, Spain.

5 <sup>2</sup>Biomedical Research Center (CINBIO), University of Vigo, 36310 Vigo, Spain.

6 <sup>3</sup>Galicia Sur Health Research Institute, 36312 Vigo, Spain.

7 <sup>4</sup>CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona,  
8 Spain

9 <sup>5</sup>Universitat Pompeu Fabra (UPF), Barcelona, Spain

10 #Equal contributions

11 §Current address: Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard, 21 Medical School, Boston,  
12 MA 02115, USA.

13 \*email: soniapradolopez@uvigo.es; dposada@uvigo.es

14 **Single-cell genomics is an alluring area that holds the potential to change the way we**  
15 **understand cell populations. Due to the small amount of DNA within a single cell, whole-genome**  
16 **amplification becomes a mandatory step in many single-cell applications. Unfortunately,**  
17 **single-cell whole-genome amplification (scWGA) strategies suffer from several technical biases**  
18 **that complicate the posterior interpretation of the data. Here we compared the performance of**  
19 **six different scWGA methods (GenomiPhi, REPLIg, TruePrime, Ampli1, MALBAC, and**  
20 **PicoPLEX) after amplifying and low-pass sequencing the complete genome of 230**  
21 **healthy/tumoral human cells. Overall, REPLIg outperformed competing methods regarding**  
22 **DNA yield, amplicon size, amplification breadth, amplification uniformity –being the only**  
23 **method with a random amplification bias–, and false single-nucleotide variant calls. On the**  
24 **other hand, non-MDA methods, and in particular Ampli1, showed less allelic imbalance and**  
25 **ADO, more reliable copy-number profiles and less chimeric amplicons. While no single scWGA**  
26 **method showed optimal performance for every aspect, they clearly have distinct advantages.**  
27 **Our results provide a convenient guide for selecting a scWGA method depending on the**  
28 **question of interest while revealing relevant weaknesses that should be considered during the**  
29 **analysis and interpretation of single-cell sequencing data.**

30 Advances in single-cell genomics have made possible the study of genomic variation at the most basic  
31 level, rapidly generating many new insights into complex biological systems, from microbial diversity  
32 to immune response, development or tumor progression<sup>1</sup>. While single-cell RNA sequencing is now  
33 mature and almost standard, single-cell DNA sequencing is still quite challenging<sup>2</sup>, mainly due to an  
34 amplification step needed before the characterization of the genome, as it is not possible to directly  
35 sequence the 6-7 pg of DNA present, for example, in a human cell. While whole-genome single-cell  
36 library preparation without preamplification is possible<sup>3</sup>, these types of techniques still include several  
37 PCR cycles, usually rely on custom-made microfluidic devices, and their implementation in a standard  
38 laboratory is far from trivial. Therefore, single-cell whole-genome amplification (scWGA) is still a  
39 prerequisite in many applications of single-cell genomics.

40 Multiple scWGA methods have been proposed, typically based on pure PCR<sup>4-7</sup>, multiple  
41 displacement amplification (MDA)<sup>8,9</sup> or a combination of both<sup>10,11</sup>, but always relying on the use of  
42 DNA polymerases. Unfortunately, the latter have a limited strand extension rate and processivity, and  
43 during scWGA lots of priming and extension reactions are required<sup>12</sup>. This large amount of reactions  
44 entails significant technical errors such as (1) allelic imbalance (AI) or allelic dropout (ADO) –when a  
45 particular allele is preferentially amplified or not amplified at all, respectively–, (2) non-uniform  
46 coverage usually attributed to GC content affecting denaturation and primer binding efficiency<sup>13-15</sup>,  
47 (3) generation of chimeric DNA molecules due to the polymerase strand displacement activity<sup>16-18</sup> and  
48 (4) false single-nucleotide variants (SNVs) owing to the infidelity of the DNA polymerase<sup>14</sup> (Fig. 1).

49 While several studies comparing the relative performance of different scWGA strategies have  
50 already been published, their scope is usually limited in terms of the sequencing target, number of  
51 scWGA methods evaluated and/or number and type of amplified cells<sup>16,17,19-30</sup> (Supplementary Table  
52 1). To date, we are not aware of any study comparing a large number of scWGA strategies on whole  
53 genomes obtained from a large number of individual cells. Here we report a comprehensive  
54 benchmark of six popular scWGA kits, including five next-generation sequencing (NGS) library  
55 preparation kits and two NGS technologies, using three human cell lines. In total, we obtained 230  
56 single-cell whole-genome sequences under 54 different scenarios (Fig. 2). We show that MDA and  
57 non-MDA methods perform differently for distinct purposes, and identify important differences within  
58 these categories. Our results should help single-cell genomics researchers choose the best  
59 amplification method for their question of interest.

## 60 **Results**

61 We assessed the performance of six scWGA commercial kits, three MDA (GenomiPhi, REPLIg and  
62 TruePrime) and three non-MDA (Ampli1, MALBAC and PicoPLEX) (Supplementary Table 2), and

63 five library preparation kits (Supplementary Table 3) in terms of amplification yield, amplicon size,  
64 coverage breadth, coverage uniformity, chimera formation, copy-number detection, allelic imbalance,  
65 ADO and false SNV detection. To do this, we obtained low-pass (0.07-1.8X) whole-genome  
66 sequencing (WGS) data from 230 individual human cells from a healthy fibroblast cell line (HDF), a  
67 colorectal cancer cell line (Caco-2), and a mantle lymphoma cell line (Z-138).

68 **DNA yield, amplicon size, and integrity.** The amount of DNA obtained with the different scWGA  
69 kits, plus the size and quality of the amplicons, could be a limitation for downstream experiments.  
70 Here, we observed statistically significant differences among the scWGA methods for DNA yield and  
71 amplicon integrity and size, independently of the cell line (Fig. 3 and Supplementary Tables 4-6).  
72 REPLiG resulted in the highest DNA yield by far with a mean value across cell lines close to 35  $\mu$ g,  
73 while the other scWGA kits produced average yields below 8  $\mu$ g (Fig. 3a and Supplementary Tables  
74 4-6). MDA approaches (GenomiPhi, REPLiG, TruePrime) produced amplicon sizes much larger than  
75 non-MDA methods (Ampli1, MALBAC, PicoPLEX) (around 10 and 1.2 kb on average, respectively),  
76 with REPLiG producing the largest amplicons (>30 kb) (Fig. 3c and Supplementary Tables 4-6). The  
77 size of the amplicons produced by the MDA kits allowed us to estimate amplicon integrity using the  
78 DNA Integrity Number (DIN) value, with REPLiG showing significantly higher values than  
79 GenomiPhi or TruePrime (Fig. 3b and Supplementary Tables 5,6). For all these three parameters,  
80 MDA methods were much more variable than non-MDA approaches, in particular in the case of  
81 REPLiG, which displayed the largest standard deviations (Supplementary Tables 4-6).

82 **Amplification breadth and uniformity.** An ideal scWGA method should provide a set of DNA  
83 molecules that represent the target genome as completely as possible. If the amplification is not  
84 uniform, different genomic regions may be missed. Here, we observed statistically significant  
85 differences among scWGA methods for amplification breadth and uniformity for the different cell  
86 lines (Fig. 4a,b). Overall, REPLiG yielded the highest amplification breadth (~50%) and TruePrime  
87 the lowest (~15%) (Fig. 4a and Supplementary Tables 4-6). In general, REPLiG also resulted in a  
88 more uniform amplification –measured by the Gini index of the Lorenz curves– than the other  
89 scWGA methods, with TruePrime performing the worst (Fig. 4b; Supplementary Fig. 1 and  
90 Supplementary Tables 4-6). Again, MDA methods were much more variable than non-MDA  
91 approaches.

92 Albeit less dramatic, the library protocol also had a significant effect on amplification breadth  
93 and uniformity. Our modified KAPA protocol provided more breadth than the other library protocols,  
94 with Ion Plus being the worst in this aspect (Fig. 4c). Also, Ion Plus and Nextera yielded overall the  
95 most and least uniform amplifications, respectively (Fig. 4d). As expected, the two sequencing

96 technologies used, Illumina and Ion Torrent, did not have a significant effect on the uniformity of the  
97 amplification. In order to better understand the joint effect of the different parameters (cell line,  
98 scWGA kit, amplification location, library kit, yield DNA, amplicon size, sequencing depth and  
99 sequencing technology) on amplification uniformity we fitted a multivariable regression model upon  
100 the Gini index values, finding that differences in amplification uniformity could be explained by the  
101 amplification kit alone.

102 **Amplification recurrence.** The coverage distribution along the genome observed for the single-cells  
103 was significantly correlated with that of the unamplified bulk (Fig. 5). Importantly, we also found that  
104 two cells amplified with the same scWGA kit showed significantly more regions in common than two  
105 cells amplified with a different scWGA kit, except for REPLiG (Fig. 5 and Supplementary Figs. 2-4).  
106 In addition, we observed that non-MDA showed a significantly higher coverage in regions with high  
107 GC content, as previously reported<sup>31</sup>. Interestingly, REPLiG showed a negative correlation of coverage  
108 with GC content whereas the other MDA methods did not show any preference based on sequence  
109 content.

110 **Chimera rates, allelic imbalance, ADO and false SNVs.** During scWGA, several artifacts can be  
111 produced, such as the formation of chimeric molecules, biased amplification of alleles, and  
112 amplification errors. These errors can easily result in incorrect genotype calls. Here we measured  
113 chimera rates, allelic imbalance, allelic dropout (ADO) and false positive variant calls (Fig. 6 and  
114 Supplementary Table 7). In this case, only the HDF cell line (4 cells per scWGA method) was used as  
115 it lacks somatic variation, which otherwise could have easily confounded these estimates. Chimera  
116 rates were much higher (>10%) for GenomiPhi and TruePrime, with Ampli1 and MALBAC showing  
117 the lowest values (Fig. 6a). When these rates were estimated upon paired-end discordant reads instead  
118 of split reads, the trends were the same but the rates were twice as high (Fig. 6b).

119 In terms of allelic imbalance and ADO rates, non-MDA methods outperformed MDA  
120 methods (Fig. 6c-e). Still, ADO rates were very high in all cases, ranging from the 38% rate of  
121 Ampli1 to the 60-90% values observed for TruePrime. REPLiG, Ampli1, and TruePrime resulted in  
122 more accurate SNV calls than the other methods (Fig. 6f,g), although the false positive rates obtained  
123 were halved depending on the variant calling approach (marginal vs joint; see methods). False SNVs  
124 were usually biased towards transitions, but different scWGA approaches showed somehow different  
125 error signatures (Supplementary Fig. 5). In the case of Ampli1, these errors showed a pattern most  
126 similar to the human germline mutational profile, in which transitions occur more than twice as often  
127 as transversions. Besides, we also found an increase in G:C>A:T errors in REPLiG and GenomiPhi.

128 **Copy-number detection.** Copy number aberrations are a fundamental type of structural variation of  
129 interest to assess genomic heterogeneity among cells. The copy-number profiles estimated from the  
130 diploid HDF cell line were generally accurate (i.e., we expect a copy number of 2 for all genomic  
131 regions) for all scWGA methods, except for TruePrime (Supplementary Fig. 6d-i). The coverage  
132 dispersion measure (MAD)<sup>32</sup> was significantly smaller for non-MDA methods, although for Caco-2  
133 REPLIg showed also very low MAD values (Supplementary Fig. 6a-c).

134 **Mapping rates and duplicated reads.** Finally, we explored the mapping rates and percentage of  
135 duplicated reads obtained. For all scWGA methods, we observed a high percentage of mapped reads  
136 (Supplementary Tables 4-6), with marginally significant differences among them ( $p$ -value = 0.04). In  
137 particular, TruePrime showed more reads mapped to the mitochondrial genome than the other scWGA  
138 kits (close to 9% in Caco-2, up to 6% in Z-138, and as high as 84.71% in HDF). Also, we detected  
139 clear mapping differences among the sequencing library kits ( $p$ -value < 2.2e-16). Within these, the  
140 library protocols that include an enrichment PCR step (SureSelect and Nextera) showed a significantly  
141 higher percentage of mapped reads ( $p$ -value = 3.8e-15). Additionally, we found a clear effect of the  
142 sequencing technology on the percentage of duplicates estimated, with Ion Torrent producing  
143 significantly more duplicates than Illumina (24% and 6%, respectively;  $p$ -value < 2.2e-16).

144 **Benchmark of the breadth and uniformity measures.** As an estimate of amplification breadth, we  
145 used low-pass sequencing data to predict the fraction of the genome covered at higher sequencing  
146 depths with the package Preseq<sup>33</sup>. To evaluate amplification uniformity, we used the Gini index or area  
147 below the coverage Lorenz curve. To validate both measurements we leveraged an *in-house* dataset of  
148 30 single cells from a Chronic Lymphocytic Leukemia (CLL) patient. The analysis of these data  
149 demonstrated that the amplification breadth prediction was very accurate (Supplementary Fig. 7). In  
150 addition, both the breadth prediction and the 1 – Gini index showed a significant positive correlation  
151 with the percentage of chromosomes amplified (Supplementary Fig. 8).

## 152 **Discussion**

153 Overall, our results show that MDA approaches (GenomiPhi, REPLIg, TruePrime) produced higher  
154 yields than non-MDA methods (Ampli1, MALBAC, PicoPLEX), which could be related to a more  
155 stable polymerase activity under isothermal conditions<sup>34</sup>. At the same time, MDA approaches  
156 generated larger amplicon sizes than non-MDA methods, likely due to a higher processing capability  
157 and template affinity of the Phi29 polymerase<sup>35</sup>. In particular, REPLIg clearly outperformed the other  
158 scWGA strategies in this aspect, possibly resulting from a higher DNA polymerase concentration<sup>36</sup>.

159 TruePrime resulted in a significantly lower coverage breadth, as previously reported<sup>28</sup>, with  
160 REPLiG outperforming the remaining methods in general, but with higher variance, as the other MDA  
161 methods. This might be explained, at least partially, by the random annealing of primers and/or more  
162 variable amplicon sizes of the MDA methods. In agreement with the coverage breadth predictions,  
163 REPLiG and TruePrime resulted in the most and least uniform amplifications, respectively, measured  
164 by the variation of the coverage along the genome. The lysis and denaturalization steps in TruePrime  
165 are made on ice, which might prevent the availability of single-stranded DNA for the primase. On the  
166 other hand, REPLiG has already been suggested to provide a more uniform coverage than non-MDA  
167 methods for few-cell amplification<sup>30</sup>.

168 The observed coverage correlation along the genome between single cells and the unamplified  
169 bulk was expected, mainly due to mappability limitations for repetitive sequences<sup>37</sup>. However, unless  
170 there is a recurrent amplification bias, we would not expect to see higher correlations among cells  
171 amplified with the same scWGA kit compared to cells amplified with a different scWGA kit, or  
172 compared with the bulk. Therefore, our results suggest that the amplification bias along the genome is  
173 not random for the different scWGA kits studied, except for REPLiG, which in most cases resulted in  
174 apparently random amplification. For non-MDA methods, spatial recurrence in the amplification is  
175 expected because they use their own set of non-random primers. For MDA methods, the results are  
176 more difficult to interpret. TruePrime uses a primase that generates its own primers<sup>9</sup>, while for both  
177 GenomiPhi and REPLiG random primers are added. However, only REPLiG showed a random  
178 amplification bias. Zhang et al.<sup>12</sup> obtained a better fit with a statistical model with random  
179 amplification bias for MDA, but they do not clarify which exact MDA method they used.

180 For the HDF cell line, non-MDA methods showed a distribution more similar to the bulk for  
181 the alternative allele frequency in heterozygous germline sites, clearly outperforming the MDA  
182 methods in terms of allelic imbalance. In particular, Ampli1 seemed to produce very low allelic  
183 imbalance. This good behavior of Ampli1 might be the result of a synthesis procedure that converts  
184 residual single-strand DNA (ssDNA) molecules into double-strand DNA (dsDNA) molecules. Also, in  
185 PicoPLEX and MALBAC the amplification is quasi-linear, therefore limiting the propagation of any  
186 allelic bias. We would like to remark that, in general, alternative allele frequency distributions are  
187 wider for our single cells than for the bulk not only because of allelic imbalance but also because they  
188 have lower coverage at the sites considered.

189 In agreement with these results –ADO is an extreme case of allelic imbalance–, non-MDA  
190 methods showed much lower ADO rates than MDA methods, in particular Ampli1, who showed the  
191 lowest ADO rate (< 40%). On the other extreme, TruePrime showed a large ADO rate (> 80%). Still,  
192 a 40% ADO rate is much higher than previously reported for Ampli1<sup>25,38,39</sup>. Although values over 40%  
193 have been already observed in other experiments for MDA methods<sup>40</sup>, here the ADO rates for



194 GenomiPhi and REPLIg were closer to 60%. Admittedly, it is possible that the absolute ADO values  
195 estimated here are somehow inflated due to the small coverage. It is well-known that at sites with low  
196 coverage there is a higher probability of missing one of the alleles by chance<sup>41</sup>. Although we have  
197 carried out this analysis on sites with at least 6X, we are aware that at this depth it is possible to  
198 incorrectly call as homozygous a truly heterozygous site. Indeed, genotyping of heterozygous sites  
199 only approximates a correct call rate of 1.0 for coverages higher than 15X<sup>42</sup>, although a threshold  
200 value of 6X has been used before to estimate ADO and false SNV rate<sup>40</sup>. In any case, the relative  
201 ADO performance should still correspond with the trend observed.

202 We used false SNVs as proxies for amplification errors. Indeed, the former also include  
203 sequencing errors, wrong SNV calls and potentially some true somatic variants, so the absolute value  
204 might be more or less inflated. However, the comparison of the false SNVs observed for each scWGA  
205 method should inform us about their relative amplification error rates. We used a PCR-free library  
206 protocol, and sequencing errors should be similar for all 24 HDF single-cell libraries, as they were  
207 included in the same sequencing run. Also, most of the true somatic variants should have been filtered  
208 out with the help of Monovar. Finally, whatever it is, the number of calling errors should be more or  
209 less constant across cells. REPLIg and TruePrime resulted in the lowest false SNV rates (< 8%  
210 depending on the genotyping approach). This might be related to the polymerase used for  
211 amplification, Phi29, which has a much lower error rate than the ones used by the other scWGA  
212 kits<sup>8,10,11,14,43-45</sup>. REPLIg was already reported as having low error rates<sup>17,28</sup>. Ampli1 also performed  
213 quite well in this regard, perhaps due to the use of a combination of Taq with a proofreading  
214 polymerase Pwo<sup>7</sup> with low error rates<sup>46</sup>. Importantly, when we used joint variant calling  
215 –incorporating population-level information–, the inferred false positive rates were halved. With  
216 regard to the type of errors observed, we found that both REPLIg and GenomiPhi resulted in an  
217 excess of C:G>T:A transitions, which has been previously attributed to high-temperature denaturation  
218 protocols, whereas the signature for Ampli1 better reflects the one expected for unamplified bulk  
219 samples<sup>47</sup>. Being aware of the existence of a different error signature for the different scWGA kits is a  
220 fact to consider if one is interested in detecting mutational signatures in single cells.

221 Our results suggest that MALBAC and Ampli1 form fewer chimeras than the other methods.  
222 Indeed, chimeras can bias the inference of structural variants. It was expected for MDA methods to  
223 perform worse than non-MDA methods in this regard, due to the Phi29 DNA polymerase strand  
224 displacement activity resulting in chimeric molecules<sup>18</sup>. However, despite the fact that REPLIg is  
225 based on MDA, it showed very low chimera rates, even lower than microfluidic protocols<sup>48</sup>. Perhaps,  
226 this might be related to larger amounts of DNA polymerase which could limit the time that ssDNA  
227 strands are naked and available for chimera formation.

228 For the HDF cell line, copy-number profiles were in general accurate for all scWGA methods  
229 except for TruePrime. In the other cell lines, the copy-number profiles were much more segmented.  
230 Nevertheless, read counts were much more dispersed for MDA methods (except for REPLIg in the  
231 HDF cell line), which could be partially explained by uneven amplification (Supplementary Fig.  
232 6a-c). Consequently, non-MDA methods would be the recommended choice for CNV analysis, as  
233 suggested before<sup>11,38</sup>.

234 Not surprisingly, the amplification protocols did not significantly affect the mapping rates.  
235 While the scWGA kit employed had a much smaller effect on the percentage of mapped reads than the  
236 library construction method –strategies with an enrichment PCR step like SureSelect and Nextera  
237 were better–, in all cases these percentages were quite high. As expected, probably due to the  
238 emulsion PCR step<sup>49</sup> included in the Ion Torrent sequencing protocol, the latter showed significantly  
239 more duplicates than Illumina.

240 In conclusion, none of the scWGA methods outperformed the others in all scenarios assessed,  
241 but clearly, some are better than others in different aspects. Here we have exposed distinct advantages  
242 and weaknesses of different scWGA methods that will be important for the interpretation and analysis  
243 of single-cell genomes.

## 244 **Methods**

245 **Cell-lines.** We used three different cell lines for the different experiments, HDF, Caco-2, and Z-138.  
246 HDF is a healthy neonatal, diploid fibroblast cell line (HDF) purchased from Sigma-Aldrich  
247 (<https://www.sigmaaldrich.com>). Caco-2 is a polyploid colorectal cancer cell line with a modal  
248 chromosome number of 96 purchased from the American Type Culture Collection (ATCC;  
249 <https://www.atcc.org>). The Z-138 is a hyperdiploid mantle cell lymphoma cell line with a modal  
250 chromosomal number of 49, also purchased from ATCC. We cultured all cell lines under an  
251 atmosphere containing 5% CO<sub>2</sub> at 37°C. We grew HDF in an all-in-one ready-to-use fibroblast growth  
252 media (Sigma-Aldrich), Caco-2 in a media consisting of Dulbecco's Modified Eagle's Medium/F12  
253 with 3.151 g/l glucose and L-glutamine (Lonza) and Z-138 with Iscove's Modified Dulbecco's  
254 Medium (ATCC). For Caco-2 and Z-138, we completed the media with 10% fetal bovine serum EU  
255 standard (Biochrom) and 1% penicillin/streptomycin (Lonza) at a working concentration of 100 units  
256 of potassium penicillin and 100 µg of streptomycin sulfate per 1 ml of culture media.

257 **Single-cell isolation.** We cultured HDF and Caco-2 cells until 80% confluence before staining with  
258 Hoechst 33342 (BD Biosciences) following the fabricant's recommendations. Thereafter, we  
259 harvested, resuspended at a concentration of 10<sup>6</sup> cells per ml in phosphate buffered saline (PBS) and



260 marked cells with propidium iodide (PI; BD Pharmingen). Then, we sorted live single cells in G0/G1  
261 with a BD Biosciences FACSAria III flow cytometer (BD Biosciences, Madrid, Spain) and collected  
262 them into 96 well plates with 1-3  $\mu$ l of PBS (Supplementary Fig. 9). For sorting, we used the BD  
263 FACSDiva v8.0.1 (BD Biosciences, Madrid, Spain) and FlowJo v7.6.2 (FlowJo, LLC, Ashland, OR,  
264 USA) for further analyses. For Z-138 we followed the same strategy but without Hoechst staining and  
265 using a FACS Aria 2.0 (BD Biosciences, Madrid, Spain) for sorting. Single cells were stored at -80 °C  
266 until amplification.

267 **Single-cell whole-genome amplification.** We used six different kits for single-cell whole-genome  
268 amplification (scWGA): Ampli1 (Silicon Biosystems), Multiple Annealing and Looping Based  
269 Amplification Cycles (MALBAC; Yukon Genomics), PicoPLEX (Rubicon Genomics), Illustra Single  
270 Cell GenomiPhi (GE Healthcare), REPLiG Single-Cell (Qiagen) and TruePrime (SYGNIS) following  
271 the manufacturer's protocols (Supplementary Table 2). In order to reduce contamination, we carried  
272 out scWGA in a laminar-flow hood using a dedicated set of pipettes and UV irradiated plastic  
273 materials. We also included positive (10 ng/ $\mu$ l REPLiG human control kit, QIAGEN) and negative  
274 (DNase/RNase free water) controls. For Ampli1 we carried a few extra steps after amplification. We  
275 used the Ampli1 QC kit to select those amplification products that were positive for four PCR  
276 markers. In order to increase the total dsDNA content, we used the Ampli1 ReAmp/ds kit. Afterwards,  
277 we removed the adaptors adding 5  $\mu$ l of NEBuffer 4 10X (New England Biolabs), 1  $\mu$ l of MseI  
278 50U/ $\mu$ l (New England Biolabs) and 19  $\mu$ l of nuclease-free water to 25  $\mu$ l of dsDNA, using a thermal  
279 cycler at 37 °C for 3 h, followed by enzyme inactivation at 65 °C for 20 min.

280 Attending to the fabricant's recommendations, we purified PicoPLEX and MALBAC products  
281 with the QIAquick PCR Purification protocol (Qiagen) and Ampli1 products with 1.8X AMPure XP  
282 beads (Agencourt, Beckman Coulter). MDA methods do not include a purification step. We measured  
283 DNA yield with a Qubit 3.0 (ThermoFisher Scientific) fluorometer and amplicon fragment size with a  
284 2200 TapeStation platform (Agilent Technologies). We measured amplicons from non-MDA based  
285 scWGA methods using the D5000 ScreenTape System and amplicons from MDA-based kits using the  
286 Genomic DNA ScreenTape System. The latter also allowed us to measure the integrity of the  
287 amplicons (DNA Integrity Number or DIN).

288 In total, we amplified 230 single-cells: 34 with Ampli1 (4 HDF, 12 Caco-2 and 18 Z-138), 40  
289 with MALBAC (4 HDF, 18 Caco-2 and 18 Z-138), 40 with PicoPLEX (4 HDF, 18 Caco-2 and 18  
290 Z-138), 37 with GenomiPhi (4 HDF, 18 Caco-2 and 15 Z-138), 35 with REPLiG (4 HDF, 16 Caco-2  
291 and 15 Z-138) and 44 with TruePrime (4 HDF, 22 Caco-2 and 18 Z-138) (Fig. 2 and Supplementary  
292 Table 2).

293 **Bulk DNA extraction.** We extracted bulk genomic DNA (gDNA) from the HDF cell line with the  
294 QIAamp DNA Mini kit (QIAGEN) according to the fabricant's recommendations. We estimated  
295 concentration and gDNA integrity as previously described for single cells.

296 **Next-generation sequencing libraries.** We built 230 single-cell whole-genome libraries employing  
297 five different library preparation kits: SureSelect<sup>QXT</sup> (Agilent Technologies), NxSeq AmpFREE Low  
298 DNA (Lucigen), Ion Plus Fragment library (ThermoFisher Scientific), Nextera DNA (Illumina) and  
299 KAPA (Kapa Biosystems). We built SureSelect and NxSeq libraries following the commercial  
300 indications while we slightly modified Ion Plus and Nextera. The sequencing facility of the National  
301 Center for Genomic Analysis (CNAG; <http://www.cnag.crg.eu>) modified the KAPA protocol to a  
302 larger extent (Supplementary Table 3). We mechanically sheared the DNA in an S2 or a LE220  
303 Focused-ultrasonicator (Covaris) for the NxSeq, Ion Plus and KAPA protocols (Supplementary Table  
304 8), while for SureSelect and Nextera we fragmented the DNA enzymatically. For Ion Plus, we  
305 included an extra purification step with AMPure XP beads (1.2X beads/sample ratio) (Agencourt,  
306 Beckman Coulter) for a better removal of NGS adaptors. For Nextera, we used 200 µl of washing  
307 buffer instead of the 300 µl recommended by the provider, the centrifugation speed was 10,000 g at  
308 room temperature (RT) for 30 s instead of 1,300 g at 20 °C for 2 min, and we used AMPure XP beads  
309 in a 0.8X ratio instead of 0.6X. In addition, we eluted the Nextera libraries in 20 µl of resuspension  
310 buffer instead of 32.5 after a 5 min air-dried step instead of 15. For the modified KAPA protocol, we  
311 carried out the end-repaired of 500 ng of sheared DNA, adenylation and ligation to Illumina specific  
312 indexed paired-end adaptors (NEXTflex-96<sup>TM</sup> DNA Barcodes, Bio Scientific). We performed the  
313 DNA size selection in two steps (0.65X and 0.85X beads/sample ratio) with AMPure XP beads in  
314 order to reach the desired fragment size (450 bp). Finally, we measured library insert sizes with a 2100  
315 Bioanalyzer High Sensitivity DNA Kit (Illumina) or a 2200 TapeStation High Sensitivity D1000 (Ion  
316 Torrent). We quantified library concentration with the Kapa Library Quantification Kit (Kapa  
317 Biosystems) for Illumina and the Ion Library Quantitation Kit (Life Technologies) for Ion Torrent.

318 In addition, we constructed a whole-genome HDF bulk library using NxSeq AmpFREE Low  
319 DNA (Lucigen) (Supplementary Table 3). We performed size selection using AMPure XP beads and  
320 we checked fragments size with the 2100 Bioanalyzer High Sensitivity DNA Kit. Finally, we  
321 quantified library concentration using the KAPA Library Quantification Kit.

322 **Whole-genome sequencing.** We sequenced single-cell libraries at shallow depths (0.07-1.76X). We  
323 sequenced 24 HDF and 166 Caco-2/Z-138 libraries on an Illumina HiSeq 4000 (PE150) or HiSeq  
324 2000 (PE125), respectively, at CNAG. We sequenced the remaining 40 libraries with an Ion Proton  
325 platform (Ion PI chip v3) at the Galician Public Foundation of Genomic Medicine (FPGMX;

326 <http://www.xenomica.eu>). We sequenced the bulk library of HDF at 30X on an Illumina HiSeq 4000  
327 (PE150) at CNAG.

328 **Preprocessing of NGS data.** We clipped library adapters and also those included in the Ampli1,  
329 PicoPLEX and MALBAC amplifications using CutAdapt (v.1.11,v.1.14)<sup>50</sup>. We mapped the sequencing  
330 reads with at least 70 bp to the human reference genome (hs37d5) with BWA-MEM  
331 (v.0.7.15-r1140)<sup>51</sup>. We sorted reads and flagged duplicates with Picard *SortSam* (v.2.2.1;  
332 <http://broadinstitute.github.io/picard>) and Picard *MarkDuplicates*, respectively. We independently  
333 mapped reads from different lanes and then merged during the duplicate marking process taking into  
334 account their read group. Regarding Ion Plus libraries, the sequencer software already removed the  
335 adapters. In order to map the reads with the Torrent Mapping Alignment Program (TMAP; v.3.4.1;  
336 <https://github.com/iontorrent/TMAP>) to the hs37d5 genome, we had to transform first of all the  
337 original BAM files to FASTQ format using Picard *SamToFastq*. We also sorted the BAM files and  
338 marked duplicates as explained above.

339 For the 24 HDF single-cells and bulk, which were subsequently used for variant calling, the base  
340 quality scores were recalibrated for each sample using GATK (v.3.7)<sup>52</sup>. Afterward, we realigned reads  
341 from the single-cells and bulk together around known indels to avoid potential false SNV calls not  
342 related to the amplification process itself but due to misalignments.

343 **Amplification breadth.** In order to approximate the amplification breadth, we calculated the  
344 percentage of the genome that would be covered by one or more reads (coverage breadth). However,  
345 we did not calculate this value directly because at very low depths this estimate is not reliable due to  
346 sampling error<sup>12</sup>. Instead, we used a method developed for single-cell libraries, implemented in the  
347 *gc\_extrap* function of the package Preseq<sup>33</sup>. For this calculation, we downsampled the BAM files to  
348 the lowest depth observed (0.07X) with Picard *DownsampleSam*. To check the quality of the Preseq  
349 prediction, we took advantage of two *in-house* datasets consisting of 30 single-cells from a patient  
350 with Chronic Lymphocytic Leukemia (CLL), that were amplified with REPLiG and sequenced twice  
351 at 0.3X-0.6X and 5X. We downsampled the former to exactly 0.1X and predicted with Preseq the  
352 percentage of the genome covered by one or more reads at 5X. Then, we compared this prediction  
353 with the values observed for the 5X dataset. In addition, we compared the Preseq prediction and the  
354 Gini index (see below) with the percentage of chromosomes amplified in the same 30 CLL single  
355 cells, according to a panel of 20 PCR markers representing all human chromosomes except 6 and 11.

356 **Amplification uniformity.** We used coverage uniformity as a surrogate for amplification uniformity.  
357 For this, we used the downsampled BAM files at 0.07X. We calculated the sequencing depth per site

358 with Bedtools<sup>53</sup> and parsed its output with an *in-house* script to create the Lorenz curves<sup>47</sup> with the *Lc*  
359 function of the *Ineq* R package. In order to quantitatively compare the Lorenz curves, we calculated  
360 the Gini index for each cell<sup>20</sup>. The Gini index measures the area below the Lorenz curve, spanning  
361 between 0 and 1, being 0 perfect uniformity and 1 perfect disuniformity, so we defined amplification  
362 uniformity as 1 minus the Gini index (see also Supplementary Fig. 1). We estimated the Gini indexes  
363 using the *Gini* function from the *Ineq* package. In order to understand which variables of the study  
364 (cell line, scWGA kit, amplification location, library kit, DNA yield, amplicon size, sequencing depth  
365 and sequencing technology) affect most the Gini index, we fitted a regression model.

366 **Amplification recurrence.** In order to understand whether a given scWGA method tends to  
367 preferentially amplify the same genomic regions in different cells compared to other scWGA methods,  
368 we counted the number of reads within non-overlapping windows of 1 Mb with Pysamstats  
369 (<https://github.com/alimanfoo/pysamstats>). For this, we used downsampled BAM files at 0.1X –after  
370 removing duplicates, secondary alignments and unmapped reads with Samtools *view*<sup>54</sup>– as input. We  
371 only used the HDF cell line for this calculation in order to avoid potential correlations among read  
372 counts due to a heterogeneous copy number in the cancer cell lines. Subsequently, we computed the  
373 Pearson correlation coefficient of the read counts between pairs of single-cells (amplified with the  
374 same scWGA kit or not) and between single-cell and bulk. We further explored the correlations  
375 between read counts and GC content in sliding windows. GC content was assessed with Bedtools *nuc*.  
376 However, since having for instance 2 reads of 150 bp mapped to the same 1 Mb window in two  
377 different single-cells does not necessarily mean that they amplify exactly the same region (in one cell  
378 reads could be mapped to the first 500 bp of the window and in the other cell to the last 500), we  
379 further explored presence/absence amplification recurrences computing Jaccard similarity  
380 coefficients. For this, we created bedGraph files for each of the single cells using Bedtools  
381 *genomecov*, simplified integer coverage values simply to 1 (presence) or 0 (absence) and then merged  
382 the resulting files using Bedtools *unionbedg* to get a matrix. We removed consecutive matrix rows  
383 which showed exactly the same presence/absence profile for the 24 HDF cells, as we wanted to be  
384 stringent and do not count several events from a single read recurrence. Then, we computed the  
385 Jaccard similarity coefficient for each pair of single-cells using the R package *jaccard*  
386 (<https://cran.r-project.org/web/packages/jaccard/index.html>). Basically, the Jaccard coefficient is  
387 computed by dividing the number of intersections (presence of coverage in both cells) between the  
388 number of total unions (presence of coverage in just one cell), this way ignoring positions without  
389 coverage for the two cells (avoiding increasing the similarity due to random absence of coverage  
390 originated by low pass sequencing). To assess its statistical significance, we implemented a  
391 permutation test using a homemade R script.

392 **Chimera formation rate.** We considered the paired-end reads mapping at a distance higher than 1 kb  
393 to result from chimeric amplicons, as well as reads with supplementary alignments (split reads). We  
394 calculated paired-end distances using Picard *CollectAlignmentSummaryMetric* and identified split  
395 reads through detection of SA:Z tags in the BAM files. For this calculation, we only used the HDF  
396 cell line in order to avoid false positives due to the high genetic instability in Caco-2 and Z-138.

397 **Allelic imbalance and ADO.** During scWGA, the two alleles of a diploid single-cell can be amplified  
398 in an unequal manner. Deviations of allele frequencies at heterozygous germline sites evince such  
399 events. If these frequencies are different from the theoretical 50%, we consider that an allelic  
400 imbalance event, and if the deviation is so high that one of the alleles is completely lost and it cannot  
401 be detected, we designate it as ADO (Fig. 1). Again, for these calculations, we only used the HDF  
402 cells, as Caco-2 and Z-138 cells present variable ploidy.

403 *Allelic imbalance.* We ran GATK *HaplotypeCaller* for the HDF bulk with the parameter  
404 `--pcr_indel_model` set to NONE. We used GATK *SelectVariants* to keep the heterozygous sites and  
405 ran GATK *VariantRecalibration* (v. 4.0.0.0) to select a high confidence set. In parallel, we created  
406 pileup files from all the HDF single-cells and bulk with Samtools *mpileup* and extracted the  
407 alternative allele fraction at the high confidence heterozygous positions using a Python script  
408 (Supplementary Information). We only considered the allele frequencies derived from sites covered by  
409 at least six reads. In order to obtain a smooth distribution from the discrete counts, we estimated the  
410 probability density function of the alternative allele fractions with the *core* R stats package, with the  
411 *bandwidth adjust* parameter set to three.

412 *Allelic dropout (ADO).* In order to measure ADO, we first had to obtain genotypes both for the bulk  
413 and the single cells. For this, we ran GATK *HaplotypeCaller* in ERC mode for all HDF single-cells  
414 and bulk independently (for the latter again setting `--pcr_indel_model` to NONE) and merged the  
415 results using two different approaches with GATK *GenotypeGVCF*. On one hand, we aggregated the  
416 bulk and the 24 single-cells (“*joint calling*”) and on the other hand, we simply combined one  
417 single-cell and the bulk one at a time (“*marginal calling*”). We counted an ADO event when the bulk  
418 was genotyped as heterozygous (AB) and the single-cell as homozygous for either the reference or the  
419 alternative allele (AA or BB) (Supplementary Fig. 10). For this calculation, we only considered  
420 positions covered by six or more reads in single cells and 15 or more reads in the bulk.

421 **Amplification polymerase errors.** We used false SNV calls (“false positives” or FP) as proxies for

422 amplification errors of the polymerase. Using the same genotypes estimated above for the ADO  
423 calculation, we counted an FP event when the bulk genotype was homozygous (AA or BB) and the  
424 single cell heterozygous (AB) (Supplementary Fig. 10). However, given the high number of somatic  
425 mutations expected to accumulate during cell growth on a plate and with the intention of mitigating  
426 their effect on the calculation of the FP rate, we did not consider for this calculation SNVs detected by  
427 the single-cell variant caller MonoVar<sup>55</sup>, nor sites with two or more reads containing the “potentially  
428 erroneous allele” in the bulk. That is, we preferred not to be very stringent and allowed one error in  
429 the bulk potentially arising by a sequencing or mapping error. Again, we only considered positions  
430 with six or more reads for single cells and 15 or more reads for the bulk. We also explored the  
431 mutational profile (signature) of the FPs directly extracting alternative and reference alleles from the  
432 marginal calling VCFs and grouped them into different categories.

433 **Copy-number detection.** The uneven distribution of the coverage, added to the existence of ADO,  
434 can make copy number detection from single-cell problematic. We compared how different scWGA  
435 kits behave in this regard using the coverage dispersion measure (MAD) explained in Garvin et al.<sup>32</sup>.  
436 For this calculation, we used the downsampled BAM files at the lowest depth for each cell line  
437 (0.25X, 0.07X, and 0.08X for HDF, Caco-2 and Z-138, respectively). We filtered out reads with a  
438 mapping quality lower than 20 from the downsampled BAMs using Samtools and created with  
439 Bedtools the BED files required to run Ginkgo<sup>32</sup>. We ran Ginkgo under default settings except for the  
440 Binning Simulation Options that were set to 150 bp reads and BWA mapping. The segmentation was  
441 inferred independently for each sample to allow a fair comparison.

442 **Statistical tests.** We calculated descriptive statistics using the *kruskal.test*, *wilcox.test*, and *cor.test*  
443 functions available in the *core* R stats package<sup>56</sup>. For the regression models, we used the R package  
444 *FWDselect*<sup>57</sup>.

#### 445 **Code availability**

446 The R and bash scripts used for this study are available as Supplementary Information.

#### 447 **Data availability**

448 Bulk and single-cell FASTQ files generated for this study have been deposited at the Sequence Read  
449 Archive (SRA) under STUDY accession SRP162960.



## 450 **Acknowledgments**

451 This work was supported by the European Research Council (ERC-617457- PHYLOCANCER  
452 awarded to D.P.) and by the Spanish Ministry of Economy and Competitiveness - MINECO  
453 (BFU2015-63774-P awarded to D.P.). D.P. receives further support from Xunta de Galicia. N.E.-G. is  
454 supported by a Ph.D. fellowship from the Galician Government (ED481A-2015/475). T.P. is now  
455 supported by a Ph.D. fellowship from the Spanish Government (FPU15/03709) and previously by a  
456 Ph.D. fellowship from the Galician Government (ED481A-2015/083). H.H. is a Miguel Servet  
457 (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). H.H. receives  
458 funding from the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P;  
459 AEI/FEDER, UE). Core funding is from the ISCIII and the Generalitat de Catalunya. CLL samples  
460 included in this study were provided by the IISGS Biobank (PT13/0010/0022), integrated into the  
461 Spanish National Biobank Network and they were processed following standard operating procedures  
462 with the appropriate approval of the Ethical and Scientific Committees. We want to thank Pilar  
463 Alvariño and people from FPGMX for their help with some of the experiments, and Laura Tomás,  
464 Fabián Crespo, Harald Detering, Xose S. Puente, Andrés Pérez-Figueroa and Joao Alves for  
465 discussions. We thank the Supercomputation Center of Galicia (CESGA) for providing computational  
466 resources.

## 467 **Author contributions**

468 N.E.-G., S.P.-L., A.G.-A. and H.H. performed the experiments. T.P. carried out the bioinformatic  
469 analyses. N.E.-G. and T.P. performed the statistical analyses. N.E.-G., T.P., S.P., and D.P. wrote the  
470 manuscript. All authors read, commented and approved the final manuscript. D.P. designed the project  
471 and supervised the whole study.

## 472 **Competing interests**

473 The authors declare no competing interests.


## 474 **References**

- 475 1. Gawad, C., Koh, W. & Quake, S. R. Single-cell genome sequencing: current state of the science.  
476 *Nat. Rev. Genet.* **17**, 175–188 (2016).
- 477 2. Linnarsson, S. & Teichmann, S. A. Single-cell genomics: coming of age. *Genome Biol.* **17**, 97  
478 (2016).
- 479 3. Zahn, H. *et al.* Scalable whole-genome single-cell library preparation without preamplification.  
480 *Nat. Methods* **14**, 167–173 (2017).
- 481 4. Nelson, D. L. *et al.* Alu polymerase chain reaction: a method for rapid isolation of  
482 human-specific sequences from complex DNA sources. *Proc. Natl. Acad. Sci. U. S. A.* **86**,


- 483 6686–6690 (1989).
- 484 5. Zhang, L. *et al.* Whole genome amplification from a single cell: implications for genetic analysis.  
485 *Proc. Natl. Acad. Sci. U. S. A.* **89**, 5847–5851 (1992).
- 486 6. Telenius, H. *et al.* Degenerate oligonucleotide-primed PCR: general amplification of target DNA  
487 by a single degenerate primer. *Genomics* **13**, 718–725 (1992).
- 488 7. Klein, C. A. *et al.* Comparative genomic hybridization, loss of heterozygosity, and DNA  
489 sequence analysis of single cells. *Proceedings of the National Academy of Sciences* **96**,  
490 4494–4499 (1999).
- 491 8. Dean, F. B. *et al.* Comprehensive human genome amplification using multiple displacement  
492 amplification. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 5261–5266 (2002).
- 493 9. Picher, Á. J. *et al.* TruePrime is a novel method for whole-genome amplification from single cells  
494 based on TthPrimPol. *Nat. Commun.* **7**, 13296 (2016).
- 495 10. Kamberov, E. *et al.* Amplification and analysis of whole genome and whole transcriptome  
496 libraries generated by a DNA polymerization process. *US Patent* (2012).
- 497 11. Zong, C., Lu, S., Chapman, A. R. & Xie, X. S. Genome-wide detection of single-nucleotide and  
498 copy-number variations of a single human cell. *Science* **338**, 1622–1626 (2012).
- 499 12. Zhang, C.-Z. *et al.* Calibrating genomic and allelic coverage bias in single-cell sequencing. *Nat.*  
500 *Commun.* **6**, 6822 (2015).
- 501 13. Hou, Y. *et al.* Single-cell exome sequencing and monoclonal evolution of a JAK2-negative  
502 myeloproliferative neoplasm. *Cell* **148**, 873–885 (2012).
- 503 14. Navin, N. E. Cancer genomics: one cell at a time. *Genome Biol.* **15**, 452 (2014).
- 504 15. Sabina, J. & Leamon, J. H. Bias in Whole Genome Amplification: Causes and Considerations.  
505 *Methods Mol. Biol.* **1347**, 15–41 (2015).
- 506 16. Voet, T. *et al.* Single-cell paired-end genome sequencing reveals structural variation per cell  
507 cycle. *Nucleic Acids Res.* **41**, 6119–6138 (2013).
- 508 17. Huang, L., Ma, F., Chapman, A., Lu, S. & Xie, X. S. Single-Cell Whole-Genome Amplification  
509 and Sequencing: Methodology and Applications. *Annu. Rev. Genomics Hum. Genet.* **16**, 79–102  
510 (2015).
- 511 18. Lasken, R. S. & Stockwell, T. B. Mechanism of chimera formation during the Multiple  
512 Displacement Amplification reaction. *BMC Biotechnol.* **7**, 19 (2007).
- 513 19. Chen, M. *et al.* Comparison of multiple displacement amplification (MDA) and multiple  
514 annealing and looping-based amplification cycles (MALBAC) in single-cell sequencing. *PLoS*  
515 *One* **9**, e114520 (2014).
- 516 20. de Bourcy, C. F. A. *et al.* A Quantitative Comparison of Single-Cell Whole Genome  
517 Amplification Methods. *PLoS One* **9**, e105585 (2014).
- 518 21. Ning, L. *et al.* Quantitative assessment of single-cell whole genome amplification methods for  
519 detecting copy number variation using hippocampal neurons. *Sci. Rep.* **5**, 11415 (2015).
- 520 22. Hou, Y. *et al.* Comparison of variations detection between whole-genome amplification methods  
521 used in single-cell resequencing. *Gigascience* **4**, 37 (2015).
- 522 23. Li, N. *et al.* The Performance of Whole Genome Amplification Methods and Next-Generation  
523 Sequencing for Pre-Implantation Genetic Diagnosis of Chromosomal Abnormalities. *J. Genet.*  
524 *Genomics* **42**, 151–159 (2015).
- 525 24. Deleye, L. *et al.* Whole genome amplification with SurePlex results in better copy number  
526 alteration detection using sequencing data compared to the MALBAC method. *Sci. Rep.* **5**, 11711  
527 (2015).
- 528 25. Babayan, A. *et al.* Comparative study of whole genome amplification and next generation

- 529 sequencing performance of single cancer cells. *Oncotarget* **8**, 56066–56080 (2016).
- 530 26. Deleye, L. *et al.* Performance of a TthPrimPol-based whole genome amplification kit for copy  
531 number alteration detection using massively parallel sequencing. *Sci. Rep.* **6**, 31825 (2016).
- 532 27. Deleye, L. *et al.* Performance of four modern whole genome amplification methods for copy  
533 number variant detection in single cells. *Sci. Rep.* **7**, 3422 (2017).
- 534 28. Biezuner, T. *et al.* Comparison of seven single cell Whole Genome Amplification commercial  
535 kits using targeted sequencing. Preprint at  
536 <https://www.biorxiv.org/content/early/2017/09/11/186940> (2017).
- 537 29. Borgström, E., Paterlini, M., Mold, J. E., Frisen, J. & Lundeberg, J. Comparison of whole  
538 genome amplification techniques for human single cell exome sequencing. *PLoS One* **12**,  
539 e0171566 (2017).
- 540 30. Deleye, L., Gansemans, Y., De Coninck, D., Van Nieuwerburgh, F. & Deforce, D. Massively  
541 parallel sequencing of micro-manipulated cells targeting a comprehensive panel of  
542 disease-causing genes: A comparative evaluation of upstream whole-genome amplification  
543 methods. *PLoS One* **13**, e0196334 (2018).
- 544 31. Benjamini, Y. & Speed, T. P. Summarizing and correcting the GC content bias in high-throughput  
545 sequencing. *Nucleic Acids Res.* **40**, e72 (2012).
- 546 32. Garvin, T. *et al.* Interactive analysis and assessment of single-cell copy-number variations. *Nat.*  
547 *Methods* **12**, 1058–1060 (2015).
- 548 33. Daley, T. & Smith, A. D. Modeling genome coverage in single-cell sequencing. *Bioinformatics*  
549 **30**, 3159–3165 (2014).
- 550 34. Pinard, R. *et al.* Assessment of whole genome amplification-induced bias through  
551 high-throughput, massively parallel whole genome sequencing. *BMC Genomics* **7**, 216 (2006).
- 552 35. Blanco, L. *et al.* Highly efficient DNA synthesis by the phage phi 29 DNA polymerase.  
553 Symmetrical mode of DNA replication. *J. Biol. Chem.* **264**, 8935–8940 (1989).
- 554 36. Dimitriadou, E., Zamani Esteki, M. & Vermeesch, J. R. Copy Number Variation Analysis by  
555 Array Analysis of Single Cells Following Whole Genome Amplification. *Methods Mol. Biol.*  
556 **1347**, 197–219 (2015).
- 557 37. Treangen, T. J. & Salzberg, S. L. Repetitive DNA and next-generation sequencing: computational  
558 challenges and solutions. *Nat. Rev. Genet.* **13**, 36–46 (2011).
- 559 38. Binder, V. *et al.* A New Workflow for Whole-Genome Sequencing of Single Human Cells. *Hum.*  
560 *Mutat.* **35**, 1260–1270 (2014).
- 561 39. Normand, E. *et al.* Comparison of three whole genome amplification methods for detection of  
562 genomic aberrations in single cells. *Prenat. Diagn.* **36**, 823–830 (2016).
- 563 40. Leung, M. L., Wang, Y., Waters, J. & Navin, N. E. SNES: single nucleus exome sequencing.  
564 *Genome Biol.* **16**, 55 (2015).
- 565 41. Nielsen, R., Paul, J. S., Albrechtsen, A. & Song, Y. S. Genotype and SNP calling from  
566 next-generation sequencing data. *Nat. Rev. Genet.* **12**, 443–451 (2011).
- 567 42. Maruki, T. & Lynch, M. Genotype Calling from Population-Genomic Sequencing Data. *G3* **7**,  
568 1393–1404 (2017).
- 569 43. Esteban, J. A., Salas, M. & Blanco, L. Fidelity of phi 29 DNA polymerase. Comparison between  
570 protein-primed initiation and DNA polymerization. *J. Biol. Chem.* **268**, 2719–2726 (1993).
- 571 44. Paez, J. G. *et al.* Genome coverage and sequence fidelity of 29 polymerase-based multiple strand  
572 displacement whole genome amplification. *Nucleic Acids Res.* **32**, e71–e71 (2004).
- 573 45. Keohavong, P. & Thilly, W. G. Fidelity of DNA polymerases in DNA amplification. *Proc. Natl.*  
574 *Acad. Sci. U. S. A.* **86**, 9253–9257 (1989).

- 573 46. McInerney, P., Adams, P. & Hadi, M. Z. Error Rate Comparison during Polymerase Chain  
574 Reaction by DNA Polymerase. *Mol. Biol. Int.* **2014**, 287430 (2014).
- 575 47. Dong, X. *et al.* Accurate identification of single-nucleotide variants in whole-genome-amplified  
576 single cells. *Nat. Methods* **14**, 491–493 (2017).
- 577 48. Hosokawa, M., Nishikawa, Y., Kogawa, M. & Takeyama, H. Massively parallel whole genome  
578 amplification for single-cell sequencing using droplet microfluidics. *Sci. Rep.* **7**, 5199 (2017).
- 579 49. Balzer, S., Malde, K., Grohme, M. A. & Jonassen, I. Filtering duplicate reads from 454  
580 pyrosequencing data. *Bioinformatics* **29**, 830–836 (2013).
- 581 50. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.  
582 *EMBnet.journal* **17**, 10 (2011).
- 583 51. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint  
584 at <https://arxiv.org/abs/1303.3997> (2013).
- 585 52. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing  
586 next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
- 587 53. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic  
588 features. *Bioinformatics* **26**, 841–842 (2010).
- 589 54. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079  
590 (2009).
- 591 55. Zafar, H., Wang, Y., Nakhleh, L., Navin, N. & Chen, K. Monovar: single-nucleotide variant  
592 detection in single cells. *Nat. Methods* **13**, 505–507 (2016).
- 593 56. R Core Team. R: A Language and Environment for Statistical Computing. (2017).
- 594 57. Sestelo, M., Villanueva, N. M., Meira-Machado, L. & Roca-Pardiñas, J. FWDselect: An R  
595 Package for Variable Selection in Regression Models. *The R Journal* **8**, (2016).




**Fig. 1 | scWGA technical errors.** On top, there is a representation of reads from a sequencing library constructed from perfectly amplified single-cell DNA material or, commonly, unamplified bulk. Reads coming from a sequencing library built from the product of a biased amplification are shown at the bottom. Single-cell amplification starts from a single pair of homologous chromosomes (Chr 1 and 2) while the unamplified bulk library is directly constructed from lots of chromosome pairs. During the amplification, which originated the second sequencing library, several biases occurred. On the one hand, some templates were not amplified at all (A: allelic dropout), or they were not copied as many times as their homologous sequences leading to a disproportion of maternal and paternal alleles (B: allelic imbalance). The latter contributes (although is not strictly required) to the coverage non-uniformity across the genome (C: Non-uniform coverage). The uneven coverage results in a decrease of the coverage breadth (proportion of genome covered by at least 1 read). On the other hand, during the amplification the DNA polymerase introduced a single-nucleotide variant not present in the original template (D: false SNV) as well as one chimeric amplicon (E: chimera), due to a replication error and a strand displacement, respectively. Discordant paired-end reads (grey stars) and split reads (green stars) reveal the presence of such chimeric amplicons. Little squares represent alternate alleles at original true germline sites (A,B) and one false SNV (D). Although amplicons are usually longer than reads, here they have been shortened to facilitate the representation.




**Fig. 2 | Experimental design.** 24 HDF single-cells, 104 Caco-2 single-cells and 102 Z-138 single-cells sorted by FACS were amplified using six scWGA methods (three MDA and three non-MDA). Sequencing libraries were constructed following four different protocols for Caco-2 and Z-138 and one for HDF. A bulk sample from the HDF cell line was also extracted and sequenced as unamplified control.







**Fig. 3 | Amplification yield. a**, DNA yield. **b**, DIN values (only MDA methods were measured). **c**, Amplicon size. Results are also shown combining the three cell lines (All). **a-c**, Boxplots: the central line indicates the median, while the box limits correspond to the Q1 and Q3 quartiles; upper and lower whiskers extend from Q3 to  $Q3 + 1.5 \times (Q3 - Q1)$  and from Q1 to  $Q1 - 1.5 \times (Q3 - Q1)$ , respectively. Kruskal-Wallis test p-values are shown for each dataset.



**Fig. 4 | Amplification breadth and uniformity.** **a,b**, Effect of the scWGA method on **(a)** predicted amplification breadth, measured by the percentage of the genome predicted to be covered at 5X, and **(b)** amplification uniformity, measured as 1 minus the Gini index of the resulting Lorenz curves, for the different scWGA kits. **c,d**, Effect of the sequencing library on **(c)** predicted amplification breadth and **(d)** amplification uniformity. **a-d**, Boxplots: the central line indicates the median, while the box limits correspond to the Q1 and Q3 quartiles; upper and lower whiskers extend from Q3 to  $Q3 + 1.5 \times (Q3 - Q1)$  and from Q1 to  $Q1 - 1.5 \times (Q3 - Q1)$ , respectively. Kruskal-Wallis test p-values are shown.



**Fig. 5 | Amplification recurrence.** Correlation plot of read counts along 1 Mb-long genome windows. The size of the dots indicates the Pearson correlation coefficient value from low (small) to high (big) and colored differently if positive (blue scale) or negative (red scale). Only statistically significant values (p-value < 0.05) are shown.



**Fig. 6 | Chimera rates, allelic imbalance, ADO and false SNV calls.** **a-g**, all these values were measured from the healthy cell line HDF. **a**, paired-end discordant reads. **b**, split reads. **c**, Kernel density estimation of the alternative allele fraction at heterozygous germline sites. Each line within a panel tab represents a different single-cell. For the density estimation we used all the positions called as heterozygous in the bulk with *HaplotypeCaller* and with at least 6 reads of coverage in the single-cells. The density of one of the REPLig single-cell is not shown as it only had 7 positions with more than 5 reads, too few to obtain a smooth distribution of the allele fraction. **d**, ADO calculated after marginal genotype calling. **e**, ADO calculated after joint genotype calling. **f**, False SNVs calculated after marginal genotype calling. **g**, False SNVs calculated after joint genotype calling. **d-g**, Boxplots: the central line indicates the median, while the box limits correspond to the Q1 and Q3 quartiles; upper and lower whiskers extend from Q3 to  $Q3 + 1.5 \times (Q3 - Q1)$  and from Q1 to  $Q1 - 1.5 \times (Q3 - Q1)$ , respectively.